BioNTech is navigating one of the most consequential transitions in its history, as the Mainz-based biotech shifts its focus squarely onto oncology while simultaneously restructuring its leadership and balance sheet. With more than 25 active clinical studies now underway — including seven late-stage readouts expected in 2026 — the company is laying the groundwork for a future independent of its blockbuster COVID-19 vaccine. That transformation took another turn this week when Cathie Wood’s ARK Invest trimmed its position in the stock, a move that comes as the founders prepare to spin off into a separate entity dedicated to next-generation mRNA technologies.
On Thursday, BioNTech shares traded at €82.15, a modest 0.31% gain from the prior close of €81.90. The uptick does little to mask a choppy week: the stock has fallen 3.75% over the past seven days. Over a 30-day horizon, however, the picture is brighter, with a gain of 9.61%. The recovery from the March 2026 low of €68.35 is now more than 20%, though the shares still sit 22.35% below the 52-week high of €105.80 reached in late January.
Chartwatchers see a mixed technical picture. The stock is trading 3.26% above its 50-day moving average of €79.55 and just above the 100-day line at €81.89. Yet it remains 3.57% below the 200-day average of €85.19, a level often viewed as a barometer of long-term sentiment. The 14-day relative strength index stands at 54.8, a neutral reading that signals no clear overbought or oversold conditions. Annualized 30-day volatility of 31.01% underlines the persistent jitters among traders.
ARK Invest’s sale on Wednesday — disclosed without a specific reason — adds a layer of headline noise to an otherwise data-driven story. The Wood-run fund has been an active investor in BioNTech in the past, and the exit of a high-profile holder can sometimes amplify short-term moves. Yet the stock barely budged on the day, suggesting that most market participants are more focused on the pipeline and the financial overhaul.
Should investors sell immediately? Or is it worth buying BioNTech?
That overhaul was laid bare in the first-quarter results released on May 5. Revenue slid to €118.1 million as COVID vaccine income continues to dwindle, leading to a net loss of €531.9 million. But the company’s cash and securities position remains formidable at €16.8 billion, and management has reaffirmed its full-year revenue guidance of €2.0 billion to €2.3 billion. To use that capital more efficiently, BioNTech announced a share buyback of up to $1 billion over twelve months, alongside a plan to streamline its production sites. The target: recurring annual savings of roughly €500 million by 2029.
The real engine of investor interest, however, is the oncology pipeline. BioNTech expects a “catalyst-rich year” with seven late-stage trial readouts, and the goal is to have 15 Phase 3 studies running by the end of 2026. Among the most closely watched assets is Pumitamig, a bispecific antibody developed with Bristol Myers Squibb. The company has launched five additional approval studies for the drug in 2026 alone, and the ongoing ROSETTA-Lung-02 trial in non-small cell lung cancer has already shown encouraging anti-tumor activity. The broader pipeline spans immunomodulators, antibody-drug conjugates, and mRNA-based cancer therapies, all built around novel combination approaches.
Perhaps the most striking strategic move involves BioNTech’s own founders. Ugur Sahin and Özlem Türeci are set to leave the company by the end of 2026 to lead a new, independent entity focused on next-generation mRNA innovation. BioNTech will contribute the relevant rights and mRNA technologies to the spin-off and receive a minority stake in return. The rationale is clear: freeing the parent company to concentrate entirely on advancing its late-stage oncology programs without the distraction of early-stage exploration. The ultimate ambition is to establish BioNTech as an industrial-scale oncology company with multiple approved products by 2030.
The coming months will put that ambition to the test. With a handful of pivotal data releases on the horizon and a cost-cutting program that touches both the factory floor and the C-suite, the stock’s trajectory will hinge on whether the science can translate into regulatory wins and, eventually, revenue. For now, the shares find themselves in a technical tug-of-war — above short-term moving averages but still looking up at the 200-day line. The next wave of trial results could be the catalyst that decides which direction they break.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 9 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 9.
BioNTech: Buy or sell? Read more here...
